75.09 -1.55 (-2.02%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 97.47 | 1-year : | 104.4 |
Resists | First : | 83.45 | Second : | 89.38 |
Pivot price | 80.38 | |||
Supports | First : | 73.85 | Second : | 61.44 |
MAs | MA(5) : | 76.3 | MA(20) : | 81.36 |
MA(100) : | 74.39 | MA(250) : | 55.67 | |
MACD | MACD : | -1.7 | Signal : | -0.8 |
%K %D | K(14,3) : | 7.4 | D(3) : | 7.6 |
RSI | RSI(14): 38.1 | |||
52-week | High : | 89.38 | Low : | 23.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NUVL ] has closed above bottom band by 17.6%. Bollinger Bands are 59.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 76.42 - 76.84 | 76.84 - 77.18 |
Low: | 72.56 - 73.15 | 73.15 - 73.64 |
Close: | 74.2 - 75.1 | 75.1 - 75.82 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Fri, 29 Mar 2024
Matthew Shair Sells 37500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock - Defense World
Fri, 29 Mar 2024
Nuvalent (NASDAQ:NUVL) Shares Down 2% on Insider Selling - Defense World
Wed, 27 Mar 2024
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $2,878,875.00 in Stock - MarketBeat
Tue, 26 Mar 2024
Nuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 20000 Shares - Defense World
Mon, 25 Mar 2024
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) - Yahoo Finance
Mon, 25 Mar 2024
Nuvalent executive sells over $1.5m in company stock By Investing.com - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 59 (M) |
Shares Float | 29 (M) |
Held by Insiders | 3.8 (%) |
Held by Institutions | 110.3 (%) |
Shares Short | 6,540 (K) |
Shares Short P.Month | 6,300 (K) |
EPS | -2.18 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 10.93 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -15.4 % |
Return on Equity (ttm) | -21.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -100 (M) |
Levered Free Cash Flow | -56 (M) |
PE Ratio | -34.61 |
PEG Ratio | 0 |
Price to Book value | 6.86 |
Price to Sales | 0 |
Price to Cash Flow | -44.15 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |